![Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial]()
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialSmith, Jaclyn A; Kitt, Michael M; Morice, Alyn H; Birring, Surinder S; McGarvey, Lorcan P; Sher, Mandel R; Li, Yu-Ping; Wu, Wen-Chi; Xu, Zhi Jin; Muccino, David R; Ford, Anthony P; Smith, Jaclyn; McGarvey, Lorcan; Birring, Surinder; Hull, James; Carr, Warner W; Goldsobel, Alan B; Gross, Gary N; Holcomb, John R; Hussain, Iftikhar; Sher, Mandel; Spangenthal, Selwyn; Storms, William; Morice, Alyn; Elkayam, David; Steven, Gary C; Krainson, James; Fakih, Faisal Alfonso; Matz, Jonathan; Brooks, Gregory Daniel; Casale, Thomas; Berman, Gary D; Condemi, John J; Greos, Leon S; Gogate, Shaila U; Sher, Ellen R; Friesen, Jason H; Schenkel, Eric J; Bernstein, David Isaac; Corren, Jonathan; Sundar, Krishna; Gotfried, Mark H; Montanaro, Anthony; Lumry, William R; Amar, Niran J; Kaplan, Michael S; Prenner, Bruce M; Murphy, Thomas R; Good, James S; Parker, Sean; Harrison, Tim; Pavord, Ian; Brightling, Christopher; Djukanovic, Ratko; McQuaid, Douglas; Denenberg, Michael; Ettinger, Neil A; Iyer, Vivek · The Lancet Respiratory Medicine · 2020